About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

CMAB vs IMAB in Metastatic Prostate Cancer

NCT00255268·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

AstraZeneca

Age

18–any

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

Histological diagnosis of D2 of Adenocarcinoma,
Naivety to treatment
Valuable bone metastasis

You may not be if

Hematological, liver or renal toxicity Grade IV
Severe and active infections

The record

StatusWithdrawn

PhasePhase 4

Taking part15

StartedAug 2004

UpdatedAug 28, 2007

Conditions

Metastatic Prostate Cancer

Where2

Research Site
Metepec, Mexico
Research Site
Mexico City, Mexico

Clareo Health | CMAB vs IMAB in Metastatic Prostate Cancer